This study by GlaxoSmithKline (GSK) looked to see how the Connected Inhaler System affected adherence to Relvar/Breo Ellipta treatment in patients with poorly controlled asthma.

Narrowing of chest coughing, wheezing, chest tightness and shortness of breath. We may have experienced some of these unpleasant symptoms at some point but for those suffering from Asthma, these are common places.  Asthma is a long term condition that often involves low adherence to treatment that may lead to poor control of symptoms.

This study wanted to know if adherence rates to inhalers – an important part of treatment – could be improved. All participants in the study used Relvar/Breo Ellipta for daily use and Salbutamol if symptoms worsened. Sensors were clipped to all inhalers to track their use.  

The 437 participants from seven countries were divided into five study groups.

Data on usages was collected in all groups. In group one participants could view data on a mobile app and the study nurse or doctor could view their data on a Connected Inhaler System. Group three, only the participants could view their data. The final group the data was collected but not seen by participants or study physicians or nurses. 

 The researchers then compared the daily adherence rates for participants. They wanted to see if adherence rates changed when the data was seen by participants, physicians, or no one. Participants data was collected for 6 months between January 2018 and January 2019, researchers compared the adherence rate between month 4 and month 6 of the study.  

The results! The study found that when participants were able to see their own data as seen in groups one they had 12% higher adherence rates compared to when no one saw the data. When both the participants and study physician or nurse could see the data there was a 9% increase in adherence rates for when no one saw the data.    

These are important results to help support proper care for those living with asthma. Connecting patients with information about their own adherence rates could be a tool to encourage adherence. 

To find out more follow up with Stephan Mark at clinicalsupporthd.gsk.com/contact.html . You can find the full study findings at  https://clinicaltrials.gov/ct2/show/NCT03380429